Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation

      Neurohormonal blockade drug therapy (NHBDT) is the cornerstone therapy in heart failure (HF) management for promoting reverse cardiac remodeling and improving outcomes. It's utility in left ventricular assist device (LVAD) supported patients remains undefined. Sixty-four patients who received continuous flow LVAD at our institution were retrospectively reviewed and divided into 2 groups: no-NHBDT group (n = 33) received LVAD support only and NHBDT group (n = 31) received concurrent NHBDT based on the clinical judgment of the attending physicians. Cardiac remodeling (echocardiographic parameters and biomarkers) and clinical outcome (functional status, HF-related hospital readmissions, and mortality) data were collected. A statistically significant increase in ejection fraction, decrease in LV end-diastolic diameter index and LV mass index, and a sustained reduction in N-terminal pro B-type natriuretic peptide (NTproBNP) were observed in the NHBDT group at 6 months after LVAD implant (p <0.05). NHBDT-treated patients experienced significantly greater improvement in New York Heart Association functional classification and 6-minute-walk distance throughout the study. The combined end point of cardiovascular death or HF hospitalization was significantly reduced in patients receiving NHBDT (p = 0.013) associated primarily with a 12.1% absolute reduction in HF-related hospitalizations (p = 0.046). In conclusion, NHBDT in LVAD-supported patients is associated with a significant reversal in adverse cardiac remodeling and a reduction in morbidity and mortality compared with LVAD support alone.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • Butler J.
        • Casey Jr., D.E.
        • Drazner M.H.
        • Fonarow G.C.
        • Geraci S.A.
        • Horwich T.
        • Januzzi J.L.
        • Johnson M.R.
        • Kasper E.K.
        • Levy W.C.
        • Masoudi F.A.
        • McBride P.E.
        • McMurray J.J.
        • Mitchell J.E.
        • Peterson P.N.
        • Riegel B.
        • Sam F.
        • Stevenson L.W.
        • Tang W.H.
        • Tsai E.J.
        • Wilkoff B.L.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62: e147-e239
        • Birks E.J.
        • Tansley P.D.
        • Hardy J.
        • George R.S.
        • Bowles C.T.
        • Burke M.
        • Banner N.R.
        • Khaghani A.
        • Yacoub M.H.
        Left ventricular assist device and drug therapy for the reversal of heart failure.
        N Engl J Med. 2006; 355: 1873-1884
        • Birks E.J.
        • George R.S.
        • Hedger M.
        • Bahrami T.
        • Wilton P.
        • Bowles C.T.
        • Webb C.
        • Bougard R.
        • Amrani M.
        • Yacoub M.H.
        • Dreyfus G.
        • Khaghani A.
        Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacologic therapy: a prospective study.
        Circulation. 2011; 123: 381-390
        • Patel S.R.
        • Saeed O.
        • Murthy S.
        • Bhatia V.
        • Shin J.J.
        • Wang D.
        • Negassa A.
        • Pullman J.
        • Goldstein D.J.
        • Maybaum S.
        Combining neurohormonal blockade with continuous-flow left ventricular assist device support for myocardial recovery: a single-arm prospective study.
        J Heart Lung Transplant. 2013; 32: 305-312
        • Jugdutt B.I.
        • Butler C.
        Ventricular unloading, tissue angiotensin II, matrix modulation, and function during left ventricular assist device support.
        J Am Coll Cardiol. 2007; 49: 1175-1177
        • Bruckner B.A.
        • Stetson S.J.
        • Perez-Verdia A.
        • Youker K.A.
        • Radovancevic B.
        • Connelly J.H.
        • Koerner M.M.
        • Entman M.E.
        • Frazier O.H.
        • Noon G.P.
        • Torre-Amione G.
        Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support.
        J Heart Lung Transplant. 2001; 20: 457-464
        • James K.B.
        • McCarthy P.M.
        • Thomas J.D.
        • Vargo R.
        • Hobbs R.E.
        • Sapp S.
        • Bravo E.
        Effect of implantable left ventricular assist device on neuroendocrine activation in heart failure.
        Circulation. 1995; 92: S191-S195
        • Klotz S.
        • Foronjy R.F.
        • Dickstein M.L.
        • Gu A.
        • Garrelds I.M.
        • Danser A.H.
        • Oz M.C.
        • D'Armiento J.
        • Burkhoff D.
        Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness.
        Circulation. 2005; 112: 364-374
        • Klotz S.
        • Danser A.H.
        • Foronjy R.F.
        • Oz M.C.
        • Wang J.
        • Mancini D.
        • D'Armiento J.
        • Burkhoff D.
        The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure.
        J Am Coll Cardiol. 2007; 49: 1166-1174
        • Klotz S.
        • Burkhoff D.
        • Garrelds I.M.
        • Boomsma F.
        • Danser A.H.
        The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin–angiotensin–aldosterone system: therapeutic consequences?.
        Eur Heart J. 2009; 30: 805-812
        • Anand I.S.
        • Fisher L.D.
        • Chiang Y.T.
        • Latini R.
        • Masson S.
        • Maggioni A.P.
        • Glazer R.D.
        • Tognoni G.
        • Cohn J.N.
        Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
        Circulation. 2003; 107: 1278-1283
        • Bittner V.
        • Weiner D.H.
        • Yusuf S.
        • Rogers W.J.
        • McIntyre K.M.
        • Bangdiwala S.I.
        • Kronenberg M.W.
        • Kostis J.B.
        • Kohn R.M.
        • Guillotte M.
        Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction.
        JAMA. 1993; 270: 1702-1707
        • Madigan J.D.
        • Barbone A.
        • Choudhri A.F.
        • Morales D.L.
        • Cai B.
        • Oz M.C.
        • Burkhoff D.
        Time course of reverse remodeling of the left ventricle during support with a left ventricular assist device.
        J Thorac Cardiovasc Surg. 2001; 121: 902-908
        • Mano A.
        • Nakatani T.
        • Oda N.
        • Kato T.
        • Niwaya K.
        • Tagusari O.
        • Nakajima H.
        • Funatsu T.
        • Hashimoto S.
        • Komamura K.
        • Hanatani A.
        • Ueda I.H.
        • Kitakaze M.
        • Kobayashi J.
        • Yagihara T.
        • Kitamura S.
        Which factors predict the recovery of natural heart function after insertion of a left ventricular assist system?.
        J Heart Lung Transplant. 2008; 27: 869-874
        • Hall S.A.
        • Cigarroa C.G.
        • Marcoux L.
        • Risser R.C.
        • Grayburn P.A.
        • Eichhorn E.J.
        Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade.
        J Am Coll Cardiol. 1995; 25: 1154-1161